Bayer Donates Antibiotic to Project HOPE to Improve Health Care for Tens of Thousands in Zanzibar
London -- Project HOPE UK will receive the antibiotic ciprofloxacin, donated by Bayer HealthCare, to improve health care for underserved communities for as many as 40,000 patients in Zanzibar.
Ciprofloxacin is an antibiotic used to treat many bacterial infections including respiratory, urinary tract, gastrointestinal, and abdominal infections.
"Thanks to Bayer, we are providing greater access to more effective medicines that result in improved care for patients in Zanzibar. Patients will leave the hospital more quickly because they now have access to a powerful antibiotic," said Ellie Higgins, Manager, Strategic Partnerships, at Project HOPE UK, a partner of Project HOPE (People-to-People Health Foundation Inc.), a global health education and humanitarian assistance organization.
The donation of over 7,000 units of ciprofloxacin tablets was presented today to the Ministry of Health in Zanzibar. The Mnazi Mmoja Hospital is the major recipient of the donated medicine as it serves one fifth of the total population in semi-autonomous Zanzibar. The antibiotic will also be delivered to rural health facilities.
"We aim to make our products accessible to as many people as possible, regardless of their income or where they live," said Professor Wolfgang Plischke, Member of the Board of Management of Bayer AG and Head of Bayer HealthCare. "We are delighted to work with the team of Project HOPE and the Ministry of Health in Zanzibar to address the medical needs of patients in Zanzibar to help speed up the recovery process for patients in need in both urban and rural communities."
Bayer HealthCare initiates and supports many cooperation projects that are committed to improving health care, in family planning, the fight against neglected and infectious diseases, training medical personnel, sexual education campaigns, or programs to give people with low incomes access to the drugs they need. In addition to donating medicines or money to overcome acute emergencies, our engagement concentrates mainly on sustainable concepts for long-term improvements in healthcare.
Detailed monitoring of the medical donation will be performed by Project HOPE and the Ministry of Health in Zanzibar to validate the distribution plans and follow up on the usage of the product.
Ciprofloxacin is a synthetic fluoroquinolone with a broad antibacterial spectrum. The primary binding site for ciprofloxacin is the gyrase-DNA complex. The inhibition of gyrase prevents nucleic acid transcription and results in a pronounced and rapid bactericidal effect. Ciprofloxacin's potency against Gram-negative bacteria is greater than it is against Gram-positive bacteria and atypical organisms.
About Project HOPE UK
Founded as an independent charitable organization in 1994, Project HOPE UK is devoted to long-term improvements in the health of vulnerable children, primarily those living in areas of poverty, conflict or other challenges that have a disproportionate negative impact on the young. Together with its work to help populations in developing countries to have access to the best available medicines, the organization is gaining growing recognition as an innovator in developing community engagement as a vehicle for sustainable and measurable advances in life-time health status of children.
About Project HOPE
Founded in 1958, Project HOPE (Health Opportunities for People Everywhere) is dedicated to providing lasting solutions to health crises, with the mission of helping people to help themselves. Identifiable to many by the SS HOPE, the world's first peacetime hospital ship, Project HOPE now conducts land-based medical training and health education programs in more than 35 countries across five continents.
About Bayer HealthCare
The Bayer Group is a global enterprise with core competencies in the fields of health care, agriculture and high-tech materials. Bayer HealthCare, a subgroup of Bayer AG with annual sales of EUR 18.6 billion (2012), is one of the world's leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Medical Care and Pharmaceuticals divisions. Bayer HealthCare's aim is to discover, develop, manufacture and market products that will improve human and animal health worldwide. Bayer HealthCare has a global workforce of 55,300 employees (Dec 31, 2012) and is represented in more than 100 countries. More information at .
Follow us on Facebook:
Follow us on Twitter:
Find more information at .
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at . The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.
((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.com on the world wide web. Inquiries to firstname.lastname@example.org)).